Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2008-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: trial isparkinsonqtpurposedelirium
  Phrases that lowered it: clinical trialcomparehepatictrial tothe use
• Sponsor's past termination rate: 5% (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 9.9% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Blinding: single (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 20 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 7846 (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 13 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium NCT01811459 · started 2013 · scored riskier than 68% of active trials completed
• Haloperidol for Delirium in Adult Critically Ill Patients NCT03628391 · started 2018 · scored riskier than 96% of active trials terminated
• Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium NCT05690698 · started 2023 · scored riskier than 14% of active trials completed
• Dexmedetomidine to Lessen Intensive Care Unit (ICU) Agitation NCT01151865 · started 2011 · scored riskier than 83% of active trials completed
• Prevention of Delirium in Intensive Care by Melatonin NCT03524937 · started 2019 · scored riskier than 63% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.